Mandy Armitage, MD

Study results show improvements in body composition, intrahepatic lipids, and cardiovascular risk markers in obese men treated with growth hormone for six months compared with placebo.

According to a recent retrospective study, orlistat is not associated with hepatotoxic effects after one year of use and it contributes to weight loss in obese patients.

Phase III studies show LDMP to be safe and effective for treatment of vasomotor symptoms in menopausal women.